Careful adjustment of Epo non-viral gene therapy for β-thalassemic anaemia treatment1Unité de Pharmacologie Chimique et Génétique, INSERM U640, Faculté de Pharmacie, 4 avenue de l'observatoire, 75006 Paris, France 2Unité de Pharmacologie Chimique et Génétique, CNRS UMR 8151, Faculté de Pharmacie, 4 avenue de l'observatoire, 75006 Paris, France 3Unité de Pharmacologie Chimique et Génétique, Université Paris Descartes, Faculté de Pharmacie, 4 avenue de l'observatoire, 75006 Paris, France 4Unité de Pharmacologie Chimique et Génétique, Ecole Nationale Supérieure de Chimie de Paris, 11 rue Pierre et Marie Curie, 75005 Paris, France 5Laboratoire de Thérapie Génique Hématopoïétique, Institut d'Hématologie (IUH), INSERM U733, Hôpital Saint-Louis, 75011 Paris, France
Genetic Vaccines and Therapy 2008, 6:10doi:10.1186/1479-0556-6-10
Additional filesAdditional file 1: Changes in erythropoietin (Epo) levels after repeated muscular electrotransfer of 1 μg and 1.5 μg of Epo-plasmid. the data provided shows the mean EPO level reached in mice following the electrotransfer treatments, for all three groups of mice (ie, control group, 1 μg treated group and 1.5 μg treated group). Mouse Epo changes in β-thalassemic mice electrotransfered with NaCl 150 mM solution for control group (solid diamond) or with 1 μg (solid sphere) and 1.5 μg (solid square) Epo-plasmid doses for the other groups. Electrotransfer was performed at day 0, 34, 112 and 215 for the three groups. One additional electrotransfer was performed at day 77 for the 1 μg group. Arrows indicate electrotransfer applications. The EPO ELISA Medac™ kit was used to measure mouse Epo based on cross-reaction (detection limit of 25 mU/ml for human Epo). Data are presented as mean Epo levels with standard error of the mean (SEM). Format: PPT Size: 38KB Download file This file can be viewed with: Microsoft PowerPoint Viewer |




on Google Scholar







author email
corresponding author email